Relating human genetic variation to variation in drug responses

Trends in Genetics

Volumn 28, Issue 10, 2012, Pages 487-495

  Madian, Ashraf G ^a   Wheeler, Heather E ^c   Jones, Richard Baker ^a,b   Dolan, M Eileen ^a,c  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

1000 genome project; Genome wide association studies; Next generation sequencing; Personalized medicine; Pharmacogenomics

Indexed keywords

ACETYLSALICYLIC ACID; ALLOPURINOL; AROMATASE INHIBITOR; BEVACIZUMAB; CARBAMAZEPINE; CISPLATIN; CITALOPRAM; CORTICOSTEROID; CRIZOTINIB; EPIRUBICIN; FENOFIBRATE; FLUCLOXACILLIN; FLUOROURACIL; GEMCITABINE; GLUCURONOSYLTRANSFERASE 1A1; INTERLEUKIN 28B; LAMOTRIGINE; OLANZAPINE; OXALIPLATIN; PEGINTERFERON; PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PERPHENAZINE; PHENYTOIN; PLACEBO; QUETIAPINE; RISPERIDONE; SORAFENIB; UNINDEXED DRUG; VEMURAFENIB; ZIPRASIDONE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ASPIRIN EXACERBATED RESPIRATORY DISEASE; BLOOD PRESSURE MONITORING; DIARRHEA; DNA POLYMORPHISM; DNA REPAIR; DNA SEQUENCE; DRUG HYPERSENSITIVITY; DRUG RESPONSE; ENDOPHENOTYPE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GRAM POSITIVE INFECTION; HUMAN; LEUKOPENIA; LIVER INJURY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTATIC MELANOMA; MICROARRAY ANALYSIS; MUCOSA INFLAMMATION; MUSCULOSKELETAL DISEASE; NAUSEA AND VOMITING; NEUROPATHY; PHARMACOGENOMICS; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN DISEASE; THROMBOCYTOPENIA;

GENETIC VARIATION; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; PHENOTYPE;

EID: 84866425246     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2012.06.008     Document Type: Review

References (105)

1. Weinshilboum R.M., Sladek S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 1980, 32:651-662.
2. Daly A.K. Genome-wide association studies in pharmacogenomics. Nat. Rev. Genet. 2010, 11:241-246.
3. Ramsey L.B., et al. Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition. Genome Res. 2012, 22:1-8.
4. Pharmacogenomics 2010, Wiley-Blackwell. L. Kager, W.E. Evans (Eds.).
5. Pearson T.A., Manolio T.A. How to interpret a genome-wide association study. JAMA 2008, 299:1335-1344.
6. Wilkening S., et al. Is there still a need for candidate gene approaches in the era of genome-wide association studies?. Genomics 2009, 93:415-419.
7. Chen S.H., et al. A genome-wide approach identifies that the aspartate metabolism pathway contributes to asparaginase sensitivity. Leukemia 2011, 25:66-74.
8. Wheeler H.E., et al. Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J. 2011, 10.1038/tpj.2011.38.
9. *5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat. Genet. 2009, 41:816-819.
10. Wadelius M., Alfirevic A. Pharmacogenomics and personalized medicine: the plunge into next-generation sequencing. Genome Med. 2011, 3:78.
11. Gunter C. Genomics: a picture worth 1000 genomes. Nat. Rev. Genet. 2010, 11:814.
12. Durbin R.M., et al. A map of human genome variation from population-scale sequencing. Nature 2010, 467:1061-1073.
13. Tatonetti N.P., et al. An integrative method for scoring candidate genes from association studies: application to warfarin dosing. BMC Bioinform. 2010, 11(Suppl. 9):S9.
14. Cooper G.M., et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 2008, 112:1022-1027.
15. Abo R., et al. Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet. Genomics 2012, 22:247-253.
16. Wilke R.A., Dolan M.E. Genetics and variable drug response. JAMA 2011, 306:306-307.
17. Shuldiner A.R., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 2009, 302:849-858.
18. Klein T.E., et al. Estimation of the warfarin dose with clinical and pharmacogenetic data. N. Engl. J. Med. 2009, 360:753-764.
19. Sagreiya H., et al. Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. Pharmacogenet. Genomics 2010, 20:407-413.
20. Epstein R.S., et al. Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J. Am. Coll. Cardiol. 2010, 55:2804-2812.
21. Gage B.F., Lesko L.J. Pharmacogenetics of warfarin: regulatory, scientific, and clinical issues. J. Thromb. Thrombolysis 2008, 25:45-51.
22. Johnson J.A., et al. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing. Clin. Pharmacol. Ther. 2011, 90:625-629.
23. Simon T., et al. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med. 2009, 360:363-375.
24. Mega J.L., et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 2009, 360:354-362.
25. Collet J.P., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009, 373:309-317.
26. Mega J.L., et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 2011, 306:2221-2228.
27. Pare G., et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 2010, 363:1704-1714.
28. Tantry U.S., et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel. The ONSET/OFFSET and RESPOND genotype studies. Circ. Cardiovasc. Genet. 2010, 3:556-566.
29. Ge D., et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009, 461:399-401.
30. Hofmann W.P., Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:257-264.
31. Suppiah V., et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009, 41:1100-1104.
32. Tanaka Y., et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009, 41:1105-1109.
33. Aparicio E., et al. IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS ONE 2010, 5:e13771.
34. Dayyeh B.K., et al. IL28B alleles exert an additive dose effect when applied to HCV-HIV coinfected persons undergoing peginterferon and ribavirin therapy. PLoS ONE 2011, 6:e25753.
35. Welsh M., et al. Pharmacogenomic discovery using cell-based models. Pharmacol. Rev. 2009, 61:413-429.
36. Wheeler H.E., Dolan M.E. Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 2012, 13:55-70.
37. Mitra A.K., et al. Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J. Pharmacol. Exp. Ther. 2011, 339:9-23.
38. Huang R.S., et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res. 2011, 17:5490-5500.
39. Ziliak D., et al. Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl. Res. 2011, 157:265-272.
40. Shukla S.J., et al. Susceptibility loci involved in cisplatin-induced cytotoxicity and apoptosis. Pharmacogenet. Genomics 2008, 18:253-262.
41. Wen Y., et al. Chemotherapeutic-induced apoptosis: a phenotype for pharmacogenomics studies. Pharmacogenet. Genomics 2011, 21:476-488.
42. Huang R.S., et al. Population differences in microRNA expression and biological implications. RNA Biol. 2011, 8:692-701.
43. Matsson P., et al. Discovery of regulatory elements in human ATP-binding cassette transporters through expression quantitative trait mapping. Pharmacogenomics J. 2011, 12:214-226.
44. Wen Y., et al. An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum. Mol. Genet. 2012, 21:1470-1480.
45. Nicolae D.L., et al. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet. 2010, 6:e1000888.
46. O'Donnell P.H., Dolan M.E. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin. Cancer Res. 2009, 15:4806-4814.
47. Wheeler H.E., et al. Genome-wide local ancestry approach identifies genes and variants associated with chemotherapeutic susceptibility in African Americans. PLoS ONE 2011, 6:e21920.
48. Dolan M.E., et al. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004, 64:4353-4356.
49. Shukla S.J., et al. Whole-genome approach implicates CD44 in cellular resistance to carboplatin. Hum. Genomics 2009, 3:128-142.
50. Peters E.J., et al. Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics 2011, 12:1407-1415.
51. Tan X.L., et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin. Cancer Res. 2011, 17:5801-5811.
52. Zhang W., et al. Evaluation of genetic variation contributing to differences in gene expression between populations. Am. J. Hum. Genet. 2008, 82:631-640.
53. Stranger B.E., et al. Genome-wide associations of gene expression variation in humans. PLoS Genet. 2005, 1:e78.
54. Gamazon E.R., et al. Exprtarget: an integrative approach to predicting human microRNA targets. PLoS ONE 2010, 5:e13534.
55. Bell J.T., et al. DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol. 2011, 12:R10.
56. Gamazon E.R., et al. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:9287-9292.
57. Hamburg M.A., Collins F.S. The path to personalized medicine. N. Engl. J. Med. 2010, 363:301-304.
58. Ong F.S., et al. Clinical utility of pharmacogenetic biomarkers in cardiovascular therapeutics: a challenge for clinical implementation. Pharmacogenomics 2012, 13:465-475.
59. Ghaddar F., et al. Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010. Pharmacogenomics 2011, 12:1051-1059.
60. Martin M.A., et al. Clinical pharmacogenetics implementation consortium guidelines for hla-B genotype and abacavir dosing. Clin. Pharmacol. Ther. 2012, 91:734-738.
61. Davis J.C., et al. The microeconomics of personalized medicine: today's challenge and tomorrow's promise. Nat. Rev. Drug Discov. 2009, 8:279-286.
62. Relling M.V., et al. Clinical implementation of pharmacogenomics: overcoming genetic exceptionalism. Lancet Oncol. 2010, 11:507-509.
63. Reese E.S., et al. Cost-effectiveness of CYP2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 2012, 32:323-332.
64. Wu A.H.B., et al. Implementation of pharmacogenomics into the clinical practice of therapeutics: issues for the clinician and the laboratorian. Pers. Med. 2009, 6:315-327.
65. Schubert C. Cancer drugs find a companion with new diagnostic tests. Nat. Med. 2011, 17:1157.
66. Relling M.V., Klein T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Pharmacol. Ther. 2011, 89:464-467.
67. Crews K.R., et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin. Pharmacol. Ther. 2012, 91:321-326.
68. Relling M.V., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin. Pharmacol. Ther. 2011, 89:387-391.
69. Scott S.A., et al. Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy. Clin. Pharmacol. Ther. 2011, 90:328-332.
70. Swen J.J., et al. Pharmacogenetics: from bench to byte. Clin. Pharmacol. Ther. 2008, 83:781-787.
71. Swen J.J., et al. Pharmacogenetics: from bench to byte: an update of guidelines. Clin. Pharmacol. Ther. 2011, 89:662-673.
72. John B., Lewis K.R. Chromosome variability and geographic distribution in insects. Science 1966, 152:711-721.
73. Gottesman I.I., Shields J. Genetic theorizing and schizophrenia. Br. J. Psychiatry 1973, 122:15-30.
74. Bearden C.E., Freimer N.B. Endophenotypes for psychiatric disorders: ready for primetime?. Trends Genet. 2006, 22:306-313.
75. Gershon E.S., Goldin L.R. Clinical methods in psychiatric genetics. I. Robustness of genetic marker investigative strategies. Acta Psychiatr. Scand. 1986, 74:113-118.
76. de Geus E.J. From genotype to EEG endophenotype: a route for post-genomic understanding of complex psychiatric disease?. Genome Med. 2010, 2:63.
77. Zou F., et al. Gene expression levels as endophenotypes in genome-wide association studies of Alzheimer disease. Neurology 2010, 74:480-486.
78. Tomaszewski M., et al. Statin-induced myopathies. Pharmacol. Rep. 2011, 63:859-866.
79. Maitland M.L., et al. Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors. J. Natl. Cancer Inst. 2010, 102:596-604.
80. Maitland M.L., et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 2009, 15:6250-6257.
81. Yanagimachi M., et al. Influence of polymorphisms within the methotrexate pathway genes on the toxicity and efficacy of methotrexate in patients with juvenile idiopathic arthritis. Br. J. Clin. Pharmacol. 2011, 71:237-243.
82. Pirmohamed M., et al. The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions. Clin. Pharmacol. Ther. 2011, 89:784-785.
83. Fernandez-Rozadilla C., et al. Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration. Pharmacogenomics J. 2012, 10.1038/tpj.2012.2.
84. Aberg K., et al. Genome-wide association study of antipsychotic-induced QTc interval prolongation. Pharmacogenomics J. 2012, 12:165-172.
85. Tanaka Y., et al. Genome-wide association study identified ITPA/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum. Mol. Genet. 2011, 20:3507-3516.
86. Tan X.-L., et al. Genetic variation predicting cisplatin cytotoxicity associated with overall survival in lung cancer patients receiving platinum-based chemotherapy. Clin. Cancer Res. 2011, 17:5801-5811.
87. Chantarangsu S., et al. Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash. Clin. Infect. Dis. 2011, 53:341-348.
88. Ingle J.N., et al. Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J. Clin. Oncol. 2010, 28:4674-4682.
89. Huang R.S., et al. Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin. Cancer Res. 2011, 17:5490-5500.
90. Tantisira K.G., et al. Genome-wide association identifies the T gene as a novel asthma pharmacogenetic locus. Am. J. Respir. Crit. Care Med. 2012, 185:1286-1291.
91. Tantisira K.G., et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. N. Engl. J. Med. 2011, 365:1173-1183.
92. *3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 2011, 20:1034-1041.
93. Innocenti F., et al. A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin. Cancer Res. 2012, 18:577-584.
94. Drago A.C., et al. The genetics of antipsychotic induced tremors: a genome-wide pathway analysis on the STEP-BD SCP sample. Am. J. Med. Genet. B 2011, 156B:975-986.
95. Garriock H.A., et al. A genomewide association study of citalopram response in major depressive disorder. Biol. Psychiatry 2010, 67:133-138.
96. Srinivasan Y., et al. Genome-wide association study of epirubicin-induced leukopenia in Japanese patients. Pharmacogenet. Genomics 2011, 21:552-558.
97. McCormack M., et al. Genome-wide mapping for clinically relevant predictors of lamotrigine- and phenytoin-induced hypersensitivity reactions. Pharmacogenomics 2012, 13:399-405.
98. Aslibekyan S., et al. A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network. Pharmacogenet. Genomics 2012, 22:191-197.
99. Tohkin M., et al. A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients. Pharmacogenomics J. 2011, 10.1038/tpj.2011.41.
100. Singer J.B., et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat. Genet. 2010, 42:711-714.
101. Kim J.-H., et al. Genome-wide and follow-up studies identify CEP68 gene variants associated with risk of aspirin-intolerant asthma. PLoS ONE 2010, 5:e13818.
102. Chung C.M., et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J. 2010, 10:537-544.
103. Lucena M.I., et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011, 141:338-347.
104. *3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med. 2011, 364:1134-1143.
105. Nicoletti P., et al. Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3. Oncologist 2012, 17:279-287.